154 related articles for article (PubMed ID: 27095388)
1. Formulation design, in vitro characterizations and anti-malarial investigations of artemether and lumefantrine-entrapped solid lipid microparticles.
Agbo C; Umeyor C; Kenechukwu F; Ogbonna J; Chime S; Lovelyn C; Agubata O; Ofokansi K; Attama A
Drug Dev Ind Pharm; 2016 Oct; 42(10):1708-21. PubMed ID: 27095388
[TBL] [Abstract][Full Text] [Related]
2. Sustained-release liquisolid compact tablets containing artemether-lumefantrine as alternate-day regimen for malaria treatment to improve patient compliance.
Nnamani PO; Ugwu AA; Ibezim EC; Kenechukwu FC; Akpa PA; Ogbonna JN; Obitte NC; Odo AN; Windbergs M; Lehr CM; Attama AA
Int J Nanomedicine; 2016; 11():6365-6378. PubMed ID: 27932882
[TBL] [Abstract][Full Text] [Related]
3. Development of artemether and lumefantrine co-loaded nanostructured lipid carriers: physicochemical characterization and in vivo antimalarial activity.
Parashar D; Aditya NP; Murthy RS
Drug Deliv; 2016; 23(1):123-9. PubMed ID: 24786480
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of novel lipid based formulation of β-Artemether and Lumefantrine in murine malaria model.
Patil S; Suryavanshi S; Pathak S; Sharma S; Patravale V
Int J Pharm; 2013 Oct; 455(1-2):229-34. PubMed ID: 23886650
[TBL] [Abstract][Full Text] [Related]
5. Nanostructured lipid carriers of artemether-lumefantrine combination for intravenous therapy of cerebral malaria.
Prabhu P; Suryavanshi S; Pathak S; Patra A; Sharma S; Patravale V
Int J Pharm; 2016 Nov; 513(1-2):504-517. PubMed ID: 27596113
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antimalarial activity by a novel artemether-lumefantrine lipid emulsion for parenteral administration.
Ma Y; Lu T; Zhao W; Wang Y; Chen T; Mei Q; Chen T
Antimicrob Agents Chemother; 2014 Oct; 58(10):5658-65. PubMed ID: 24982079
[TBL] [Abstract][Full Text] [Related]
7. Formulation development and evaluation of the anti-malaria properties of sustained release artesunate-loaded solid lipid microparticles based on phytolipids.
Chinaeke EE; Chime SA; Onyishi VI; Attama AA; Okore VC
Drug Deliv; 2015; 22(5):652-65. PubMed ID: 24479677
[TBL] [Abstract][Full Text] [Related]
8. Preparation of novel solid lipid microparticles loaded with gentamicin and its evaluation in vitro and in vivo.
Umeyor EC; Kenechukwu FC; Ogbonna JD; Chime SA; Attama A
J Microencapsul; 2012; 29(3):296-307. PubMed ID: 22283701
[TBL] [Abstract][Full Text] [Related]
9. Development of hot melt co-formulated antimalarial solid dispersion system in fixed dose form (ARLUMELT): Evaluating amorphous state and in vivo performance.
Fule R; Dhamecha D; Maniruzzaman M; Khale A; Amin P
Int J Pharm; 2015 Dec; 496(1):137-56. PubMed ID: 26471056
[TBL] [Abstract][Full Text] [Related]
10. Formulation, characterization and anti-malarial activity of homolipid-based artemether microparticles.
Agubata CO; Nzekwe IT; Attama AA; Mueller-Goymann CC; Onunkwo GC
Int J Pharm; 2015 Jan; 478(1):202-222. PubMed ID: 25448583
[TBL] [Abstract][Full Text] [Related]
11. In-situ single pass intestinal permeability and pharmacokinetic study of developed Lumefantrine loaded solid lipid nanoparticles.
Garg A; Bhalala K; Tomar DS; Wahajuddin
Int J Pharm; 2017 Jan; 516(1-2):120-130. PubMed ID: 27989820
[TBL] [Abstract][Full Text] [Related]
12. Improved pharmacokinetic and pharmacodynamic attributes of artemether-lumefantrine-loaded solid SMEDDS for oral administration.
Bhandari S; Bhandari V; Sood J; Jaswal S; Rana V; Bedi N; Sehgal R; Tiwary AK
J Pharm Pharmacol; 2017 Nov; 69(11):1437-1446. PubMed ID: 28809448
[TBL] [Abstract][Full Text] [Related]
13. Formulation and evaluation of novel solid lipid microparticles as a sustained release system for the delivery of metformin hydrochloride.
Momoh MA; Kenechukwu FC; Attama AA
Drug Deliv; 2013; 20(3-4):102-11. PubMed ID: 23650987
[TBL] [Abstract][Full Text] [Related]
14. Sustained-release diclofenac potassium-loaded solid lipid microparticle based on solidified reverse micellar solution: in vitro and in vivo evaluation.
Chime SA; Attama AA; Builders PF; Onunkwo GC
J Microencapsul; 2013; 30(4):335-45. PubMed ID: 23057661
[TBL] [Abstract][Full Text] [Related]
15. Improved antimalarial activity of caprol-based nanostructured lipid carriers encapsulating artemether-lumefantrine for oral administration.
Akpa PA; Ugwuoke JA; Attama AA; Ugwu CN; Ezeibe EN; Momoh MA; Echezona AC; Kenechukwu FC
Afr Health Sci; 2020 Dec; 20(4):1679-1697. PubMed ID: 34394228
[TBL] [Abstract][Full Text] [Related]
16. Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects.
Abdulla S; Amuri B; Kabanywanyi AM; Ubben D; Reynolds C; Pascoe S; Fitoussi S; Yeh CM; Nuortti M; Séchaud R; Kaiser G; Lefèvre G
Malar J; 2010 Sep; 9():253. PubMed ID: 20815879
[TBL] [Abstract][Full Text] [Related]
17. Engineering of microcomplex of artemether and lumefantrine for effective drug treatment in malaria.
Shende P; Desai P; Gaud RS; Dhumatkar R
Artif Cells Nanomed Biotechnol; 2017 Dec; 45(8):1597-1604. PubMed ID: 27966371
[TBL] [Abstract][Full Text] [Related]
18. Artemether-lumefantrine nanostructured lipid carriers for oral malaria therapy: Enhanced efficacy at reduced dose and dosing frequency.
Prabhu P; Suryavanshi S; Pathak S; Sharma S; Patravale V
Int J Pharm; 2016 Sep; 511(1):473-487. PubMed ID: 27421912
[TBL] [Abstract][Full Text] [Related]
19. Formulation in vitro and in vivo evaluation of SRMS-based heterolipid-templated homolipid delivery system for diclofenac sodium.
Mumuni M; Attama AA; Kunle OO
Drug Deliv; 2016; 23(3):917-25. PubMed ID: 24959939
[TBL] [Abstract][Full Text] [Related]
20. A new lipid-based oral delivery system of erythromycin for prolong sustain release activity.
Momoh MA; Ossai EC; Chidozie OE; Precscila OO; Kenechukwu FC; Ofokansi KO; Attama AA; Olobayo KO
Mater Sci Eng C Mater Biol Appl; 2019 Apr; 97():245-253. PubMed ID: 30678909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
